Jun 01, 2021
acx
Read on (unread)

What Do Treatments For Accelerated Aging Tell Us About Normal Aging?

We can prevent young people from being old, but preventing old people from being old sounds also sounds useful.
Scott Alexander examines the treatment for progeria and its potential implications for understanding and treating normal aging processes. Longer summary
This post discusses the implications of progeria treatments for understanding normal aging. Scott Alexander explores the recent FDA approval of lornafarnib for Hutchinson-Gilford Progeria Syndrome and its potential relevance to normal aging processes. He explains the cellular mechanisms behind progeria, involving defective lamin A protein production, and how this leads to accelerated aging through DNA damage accumulation. While initially concluding that lornafarnib might not help prevent normal aging, Scott then presents research suggesting that similar protein defects might play a role in normal aging processes. The post ends with uncertainty about the extent to which these mechanisms contribute to regular aging. Shorter summary

Progeria is a rare disease that makes people age unnaturally quickly. Babies born with progeria can lose their hair in toddlerhood, get wrinkles by grade school age, and die - apparently of old age - in their early teens. You can see a picture of a progeroid child here, though I don't recommend it.

There's been a lot of research on one important form - Hutchinson-Gilford Syndrome - and just last year, the FDA approved the first treatment, a drug called lornafarnib. In the study, a few hundred children averaging around 7 years old took the drug for two years; 3% died during that time. In an ad hoc group of untreated comparison children, about 30% died during the same period. I'm a little confused by the methodology - it seems like the "comparison children" were chosen partly because they died too early to get into the trial, which sounds like a pretty major confounder - but everyone seems to treat this as reasonable so I will assume they adjusted for this in some way. If that's true, then lornafarnib cuts mortality by 90%.

That's great for the 300 or so children worldwide with Hutchinson-Gilford progeria (it's a really rare disease). But none of the discussion about this answered the question I wanted to know: can lornafarnib also prevent normal aging?

After looking into this more, I find some evidence the the answer is no, but also some reasons why maybe it's less clear cut than that?

Hutchinson-Gilford progeria (I'll just say "progeria" from here on, even though that's kind of inaccurate) is what's called a laminopathy. It's a disease of the nuclear lamina, a weblike structure that helps support and give shape to the cell nucleus. The lamina is partly made of a protein called lamin A. Children with progeria have a mutation in the relevant gene; instead of producing lamin A, they produce a defective mutant protein called progerin. The cell tries to build the nuclear lamina out of defective progerin instead of normal lamin A, and as a result the cell nucleus is screwed up and can't maintain a normal shape.

So then aging happens? My sources don't seem to have a great explanation of this. The UniProt database says that this "acts to deregulate mitosis and DNA damage signaling, leading to premature cell death and senescence". This paper goes a little further, saying that the screwiness in the nuclear lamina prevents DNA repair proteins from doing their job.

Many different processes cause aging, but one of those processes is accumulation of DNA damage. Sometimes this makes cells do their jobs less well. Other times it shifts them into a state euphemistically termed "senescence", where they realize something is wrong, chemically "scream" for the immune system to come kill them, but the immune system is overtaxed and so they just sit there screaming out more and more chemicals and poisoning everything around them.

So a unified theory of progeria goes: the lamin mutation causes accumulation of defective protein in the nucleus, preventing DNA repair. This makes people accumulate DNA damage faster, and since DNA damage is a major cause of aging, it makes these people age more quickly.

Lornafarnib interferes with the production of the defective progerin protein. As best I can tell, it doesn't cause the cell to produce healthy lamin A - it just prevents the defective mutant version from accumulating. For whatever reason, the cells without lamin A do surprisingly okay as long as they don't have the defective mutant version. So this prevents most of the DNA repair problems, and so decreases premature aging.

All of this suggests lornafarnib shouldn't help prevent normal aging. After all, normal aging is caused by lots of processes including gradual expected accumulation of DNA damage - not just the downstream effects of one weird mutant protein.

...except that in doing this research I kept finding people saying that maybe some of aging is caused by this one weird mutant protein. I don't claim to fully understand Scaffidi and Misteli, but they write:

Age-related nuclear defects are caused by sporadic use, in healthy individuals, of the same cryptic splice site in lamin A whose constitutive activation causes [Hutchinson-Gilford progeria]. Inhibition of this splice site reverses the nuclear defects associated with aging. These observations implicate lamin A in physiological aging.

Musich and Zou write, in a way that doesn't quite let me trace back their reasoning:

It is quite likely that the same sporadic abnormal splicing of prelamin A mRNA is responsible for the genome instability in both HGPS and normal aging.

I don't really get what's going on here. I know that often, as age-related damage degrades DNA, a lot of weird malformed proteins pop up and accumulate - for example, the beta amyloid plaques that might (or might not) be involved in Alzheimers. Maybe progerin is one of these proteins and causes some of the problems commonly associated with aging? But what percent of the problems? If it and 99 other defective proteins each cause 1%, not really a big deal. If it's 50%, bigger deal - but nothing is ever that easy.

If you enjoy this fan website, you can support us over here. Thanks a lot!
Send this article to your Kindle or e-reader

We'll email you this article as an EPUB attachment, ready to open on your Kindle, Kobo, or any other e-reader.

To send to your Kindle, just use this link.

Enter your Send-to-Kindle email (it looks like [email protected]) below. For Amazon to accept the file, you first need to add our sender address to your approved list:

[email protected]

Open Amazon approved emails settings

On that page, open "Personal Document Settings", then add the address above under "Approved Personal Document E-mail List".

If your Kindle is linked to a non-US Amazon account, change the link's domain to match your country (for example amazon.fr or amazon.co.uk instead of amazon.com).

Email address
Enjoying this website? You can donate to support it! You can also check out my Book Translator tool.